Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Afatinib Dimaleate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 20,787Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eugia Pharma`s Generics Afatinib Receives Approval in US
    Eugia Pharma`s Generics Afatinib Receives Approval in US

    23 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210770

    FDA
    23 Sep 2024
    Share Share
    Sun Pharm`s Generic Afatinib Receives Tentative Approval In US
    Sun Pharm`s Generic Afatinib Receives Tentative Approval In US

    06 Nov 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210814

    FDA
    06 Nov 2020
    Share Share
    Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data
    Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data

    17 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/daiichi-sankyo-announces-late-breaking-phase-1-dose-expansion-data-for-patritumab-deruxtecan-in-patients-with-egfr-mutated-nsclc-at-esmo-2020/?s=73

    BIOSPACE
    17 Sep 2020
    Share Share
    New uncommon EGFR mutations database published featuring clinical outcomes NSCLC
    New uncommon EGFR mutations database published featuring clinical outcomes NSCLC

    16 Mar 2020

    // PRESS RELEASE

    https://www.boehringer-ingelheim.com/press-release/uncommonmutationsdatabase

    PRESS RELEASE
    16 Mar 2020
    Share Share
    J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
    J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

    11 Mar 2020

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/j_and_js_bispecific_lung_cancer_antibody_nabs_fda_breakthrough_status_1328830

    Phil Taylor PMLIVE
    11 Mar 2020
    Share Share
    Additional data for Boehringer's Giotrif combo shows benefit in lung cancer
    Additional data for Boehringer's Giotrif combo shows benefit in lung cancer

    05 Aug 2019

    // PHARMAFILE

    http://www.pharmafile.com/news/525736/additional-data-boehringers-giotrif-combo-shows-strong-overall-survival-benefit-lung-can

    PHARMAFILE
    05 Aug 2019
    Share Share